{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:45:07Z","timestamp":1793112307661,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04581-y","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:05:42Z","timestamp":1767960342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lecanemab treatment for mild alzheimer\u2019s disease with high risk of cerebral hemorrhage: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Qi","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"L\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"4581_CR1","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer\u2019s disease. Nat Rev Dis Primers. 2015;1:15056.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4581_CR2","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1038\/s41598-021-83585-3","volume":"11","author":"SH Cho","year":"2021","unstructured":"Cho SH, Woo S, Kim C, Kim HJ, Jang H, Kim BC, Kim SE, Kim SJ, Kim JP, Jung YH, et al. Disease progression modelling from preclinical alzheimer\u2019s disease (AD) to AD dementia. Sci Rep-Uk. 2021;11(1):4168.","journal-title":"Sci Rep-Uk"},{"issue":"9","key":"4581_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38(9):1205\u201335.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"4581_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, Giorgi L, Gee M, Kanekiyo M, Li D, et al. Updated safety results from phase 3 Lecanemab study in early alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):105.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"4581_CR5","first-page":"359","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM, Lecanemab. First Approval Drugs. 2023;83(4):359\u201365.","journal-title":"First Approval Drugs"},{"issue":"3","key":"4581_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, et al. Lecanemab: appropriate use recommendations. Jpad-J Prev Alzheim. 2023;10(3):362\u201377.","journal-title":"Jpad-J Prev Alzheim"},{"issue":"1","key":"4581_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in early alzheimer\u2019s disease. New Engl J Med. 2023;388(1):9\u201321.","journal-title":"New Engl J Med"},{"issue":"3","key":"4581_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-Related imaging abnormalities and beta-Amyloid-Targeting antibodies: A systematic review. Jama Neurol. 2022;79(3):291\u2013304.","journal-title":"Jama Neurol"},{"issue":"11","key":"4581_CR9","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll J, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146(11):4414\u201324.","journal-title":"Brain"},{"issue":"1","key":"4581_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30\u201342.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"4581_CR11","doi-asserted-by":"publisher","first-page":"e208096","DOI":"10.1212\/WNL.0000000000208096","volume":"102","author":"J Hardy","year":"2024","unstructured":"Hardy J, Schott JM. Identifying genetic risk for Amyloid-Related imaging abnormalities. Neurology. 2024;102(3):e208096.","journal-title":"Neurology"},{"issue":"10","key":"4581_CR12","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3174\/ajnr.A3500","volume":"34","author":"J Barakos","year":"2013","unstructured":"Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, Tampieri D, Melancon D, Miaux Y, Rippon G, et al. MR imaging features of amyloid-related imaging abnormalities. Am J Neuroradiol. 2013;34(10):1958\u201365.","journal-title":"Am J Neuroradiol"},{"issue":"3","key":"4581_CR13","doi-asserted-by":"publisher","first-page":"e207919","DOI":"10.1212\/WNL.0000000000207919","volume":"102","author":"SJ Loomis","year":"2024","unstructured":"Loomis SJ, Miller R, Castrillo-Viguera C, Umans K, Cheng W, O\u2019Gorman J, Hughes R, Budd HS, Whelan CD. Genome-Wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies. Neurology. 2024;102(3):e207919.","journal-title":"Neurology"},{"issue":"1","key":"4581_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/STROKEAHA.121.036873","volume":"53","author":"L Sveikata","year":"2022","unstructured":"Sveikata L, Charidimou A, Viswanathan A. Vessels Sing their arias: the role of vascular amyloid in the age of aducanumab. Stroke. 2022;53(1):298\u2013302.","journal-title":"Stroke"},{"key":"4581_CR15","doi-asserted-by":"publisher","first-page":"1326784","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci-Switz. 2024;18:1326784.","journal-title":"Front Neurosci-Switz"},{"key":"4581_CR16","doi-asserted-by":"crossref","unstructured":"Bilodeau PA, Dickson JR, Kozberg MG. The impact of Anti-Amyloid immunotherapies on stroke care. J Clin Med. 2024;13(5):1245.","DOI":"10.3390\/jcm13051245"},{"issue":"8","key":"4581_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.7326\/0003-4819-159-8-201310150-00004","volume":"159","author":"MH Li","year":"2013","unstructured":"Li MH, Chen SW, Li YD, Chen YC, Cheng YS, Hu DJ, Tan HQ, Wu Q, Wang W, Sun ZK, et al. Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: a cross-sectional study. Ann Intern Med. 2013;159(8):514\u201321.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4581_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12028-022-01476-5","volume":"37","author":"W Wahood","year":"2022","unstructured":"Wahood W, Rizvi AA, Alexander AY, Yolcu YU, Lanzino G, Brinjikji W, Rabinstein AA. Trends in admissions and outcomes for treatment of aneurysmal subarachnoid hemorrhage in the united States. Neurocrit Care. 2022;37(1):209\u201318.","journal-title":"Neurocrit Care"},{"issue":"4","key":"4581_CR19","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1161\/STROKEAHA.108.531277","volume":"40","author":"JM Visser-Meily","year":"2009","unstructured":"Visser-Meily JM, Rhebergen ML, Rinkel GJ, van Zandvoort MJ, Post MW. Long-term health-related quality of life after aneurysmal subarachnoid hemorrhage: relationship with psychological symptoms and personality characteristics. Stroke. 2009;40(4):1526\u20139.","journal-title":"Stroke"},{"issue":"26","key":"4581_CR20","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1056\/NEJMoa1113260","volume":"366","author":"A Morita","year":"2012","unstructured":"Morita A, Kirino T, Hashi K, Aoki N, Fukuhara S, Hashimoto N, Nakayama T, Sakai M, Teramoto A, Tominari S, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. New Engl J Med. 2012;366(26):2474\u201382.","journal-title":"New Engl J Med"},{"issue":"10","key":"4581_CR21","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaneurol.2021.2915","volume":"78","author":"LT van der Kamp","year":"2021","unstructured":"van der Kamp LT, Rinkel G, Verbaan D, van den Berg R, Vandertop WP, Murayama Y, Ishibashi T, Lindgren A, Koivisto T, Teo M, et al. Risk of rupture after intracranial aneurysm growth. Jama Neurol. 2021;78(10):1228\u201335.","journal-title":"Jama Neurol"},{"issue":"1","key":"4581_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1474-4422(13)70263-1","volume":"13","author":"JP Greving","year":"2014","unstructured":"Greving JP, Wermer MJ, Brown RJ, Morita A, Juvela S, Yonekura M, Ishibashi T, Torner JC, Nakayama T, Rinkel GJ, et al. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. Lancet Neurol. 2014;13(1):59\u201366.","journal-title":"Lancet Neurol"},{"issue":"2","key":"4581_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1227\/01.NEU.0000316847.64140.81","volume":"63","author":"S Dhar","year":"2008","unstructured":"Dhar S, Tremmel M, Mocco J, Kim M, Yamamoto J, Siddiqui AH, Hopkins LN, Meng H. Morphology parameters for intracranial aneurysm rupture risk assessment. Neurosurgery. 2008;63(2):185\u201396.","journal-title":"Neurosurgery"},{"issue":"12","key":"4581_CR24","doi-asserted-by":"publisher","first-page":"9057","DOI":"10.1007\/s00330-021-08340-8","volume":"31","author":"A Rau","year":"2021","unstructured":"Rau A, Urbach H. The MTA score-simple and reliable, the best for now? Eur Radiol. 2021;31(12):9057\u20139.","journal-title":"Eur Radiol"},{"issue":"10","key":"4581_CR25","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","volume":"72","author":"S Schreiber","year":"2015","unstructured":"Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ. Comparison of visual and quantitative Florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes. Jama Neurol. 2015;72(10):1183\u201390.","journal-title":"Jama Neurol"},{"issue":"11","key":"4581_CR26","first-page":"CD012216","volume":"11","author":"G Martinez","year":"2017","unstructured":"Martinez G, Vernooij RW, Fuentes PP, Zamora J, Bonfill CX, Flicker L. 18F PET with Florbetapir for the early diagnosis of alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Db Syst Rev. 2017;11(11):CD012216.","journal-title":"Cochrane Db Syst Rev"},{"issue":"1","key":"4581_CR27","first-page":"e12190","volume":"13","author":"MR Campbell","year":"2021","unstructured":"Campbell MR, Ashrafzadeh-Kian S, Petersen RC, Mielke MM, Syrjanen JA, van Harten AC, Lowe VJ, Jack CJ, Bornhorst JA, Algeciras-Schimnich A. P-tau\/Abeta42 and Abeta42\/40 ratios in CSF are equally predictive of amyloid PET status. Alzh Dement-Dadm. 2021;13(1):e12190.","journal-title":"Alzh Dement-Dadm"},{"issue":"4","key":"4581_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CJ Jack","year":"2018","unstructured":"Jack CJ, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"4581_CR29","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably E, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"5\u20136","key":"4581_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s007020200068","volume":"109","author":"KA Jellinger","year":"2002","unstructured":"Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm. 2002;109(5\u20136):813\u201336.","journal-title":"J Neural Transm"},{"issue":"2","key":"4581_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1046\/j.1365-2990.2003.00424.x","volume":"29","author":"SD Preston","year":"2003","unstructured":"Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in alzheimer\u2019s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropath Appl Neuro. 2003;29(2):106\u201317.","journal-title":"Neuropath Appl Neuro"},{"key":"4581_CR32","doi-asserted-by":"publisher","first-page":"1412006","DOI":"10.3389\/fnagi.2024.1412006","volume":"16","author":"KE Foley","year":"2024","unstructured":"Foley KE, Wilcock DM. Three major effects of APOE(epsilon4) on Abeta immunotherapy induced ARIA. Front Aging Neurosci. 2024;16:1412006.","journal-title":"Front Aging Neurosci"},{"key":"4581_CR33","doi-asserted-by":"crossref","unstructured":"Banerjee G, Samra K, Adams ME, Jaunmuktane Z, Parry-Jones AR, Grieve J, Toma AK, Farmer SF, Sylvester R, Houlden H, et al. Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. J Neurol Neurosur Ps. 2022:jnnp-2022\u2013328792.","DOI":"10.1136\/jnnp-2022-328792"},{"issue":"5","key":"4581_CR34","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/STROKEAHA.122.041690","volume":"54","author":"K Kaushik","year":"2023","unstructured":"Kaushik K, van Etten ES, Siegerink B, Kappelle LJ, Lemstra AW, Schreuder F, Klijn C, Peul WC, Terwindt GM, van Walderveen M, et al. Iatrogenic cerebral amyloid angiopathy post neurosurgery: Frequency, clinical Profile, radiological Features, and outcome. Stroke. 2023;54(5):1214\u201323.","journal-title":"Stroke"},{"key":"4581_CR35","doi-asserted-by":"publisher","unstructured":"Kobayashi Y, Kurashina M, Sasaki T, Yoshinaga T, Sekijima Y. Rapid progression of cerebral amyloid angiopathy following coil embolization for vertebral artery dissection: A case report. Acta Neurol Belg. 2025. https:\/\/doi.org\/10.1007\/s13760-025-02885-x.","DOI":"10.1007\/s13760-025-02885-x"},{"issue":"5","key":"4581_CR36","doi-asserted-by":"publisher","first-page":"100160","DOI":"10.1016\/j.tjpad.2025.100160","volume":"12","author":"C Chen","year":"2025","unstructured":"Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K, Ogawa T, Dash A, Irizarry M, Dhadda S, et al. Clarity AD: Asian regional analysis of a phase III trial of Lecanemab in early alzheimer\u2019s disease. Jpad-J Prev Alzheim. 2025;12(5):100160.","journal-title":"Jpad-J Prev Alzheim"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04581-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04581-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:01:00Z","timestamp":1770390060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-025-04581-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4581"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04581-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was approved by the Medical Research Ethics Committee of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China (Approval No. 2025-254-02). We certify that the study was performed in accordance with the 1964 declaration of HELSINKI and later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of this case report and any accompanying images was obtained from the patient and his legal guardian, given the patient\u2019s diagnosis of Alzheimer\u2019s disease and the potential limitations in decision-making capacity. The patient was found to have impaired decision-making capacity upon evaluation by two experienced physicians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}